Comparative efficacy of biologic therapy in biologic-naïve patients with Crohn disease: A systematic review and network meta-analysis

Mayo Clinic Proceedings

Volumn 89, Issue 12, 2014, Pages 1621-1635

  Singh, Siddharth ^a   Garg, Sushil Kumar ^b   Pardi, Darrell S ^a   Wang, Zhen ^a   Hassan Murad, Mohammad ^a   Loftus, Edward V ^a  

^a MAYO CLINIC   (United States)

^b UNIVERSITY OF MINNESOTA MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADALIMUMAB; CERTOLIZUMAB PEGOL; INFLIXIMAB; NATALIZUMAB; PLACEBO; USTEKINUMAB; VEDOLIZUMAB; IMMUNOGLOBULIN F(AB) FRAGMENT; IMMUNOSUPPRESSIVE AGENT; MACROGOL DERIVATIVE; MONOCLONAL ANTIBODY;

BAYES THEOREM; CROHN DISEASE; DISEASE SEVERITY; DRUG EFFICACY; DRUG EXPOSURE; DRUG RESPONSE; HUMAN; META ANALYSIS; RANDOMIZED CONTROLLED TRIAL (TOPIC); REMISSION; REVIEW; SYSTEMATIC REVIEW; ADULT; COMPARATIVE STUDY; PROCEDURES; TREATMENT OUTCOME;

ADULT; ANTIBODIES, MONOCLONAL; ANTIBODIES, MONOCLONAL, HUMANIZED; CROHN DISEASE; HUMANS; IMMUNOGLOBULIN FAB FRAGMENTS; IMMUNOSUPPRESSIVE AGENTS; POLYETHYLENE GLYCOLS; REMISSION INDUCTION; TREATMENT OUTCOME;

EID: 84919862319     PISSN: 00256196     EISSN: 19425546     Source Type: Journal    
DOI: 10.1016/j.mayocp.2014.08.019     Document Type: Article

References (45)

1. N.A. Molodecky, I.S. Soon, and D.M. Rabi Increasing incidence and prevalence of the inflammatory bowel diseases with time, based on systematic review Gastroenterology 142 1 2012 46 54.e42 quiz e30
2. K.T. Park, and D. Bass Inflammatory bowel disease-attributable costs and cost-effective strategies in the United States: a review Inflamm Bowel Dis 17 7 2011 1603 1609
3. J.F. Colombel, W.J. Sandborn, W. Reinisch SONIC Study Group Infliximab, azathioprine, or combination therapy for Crohn's disease N Engl J Med 362 15 2010 1383 1395
4. S.B. Hanauer, B.G. Feagan, G.R. Lichtenstein ACCENT I Study Group Maintenance infliximab for Crohn's disease: the ACCENT I randomised trial Lancet 359 9317 2002 1541 1549
5. J.F. Colombel, W.J. Sandborn, and P. Rutgeerts Adalimumab for maintenance of clinical response and remission in patients with Crohn's disease: the CHARM trial Gastroenterology 132 1 2007 52 65
6. M. Watanabe, T. Hibi, and K.G. Lomax Adalimumab for the induction and maintenance of clinical remission in Japanese patients with Crohn's disease J Crohns Colitis 6 2 2012 160 173
7. W.J. Sandborn, B.G. Feagan, S. Stoinov PRECISE 1 Study Investigators Certolizumab pegol for the treatment of Crohn's disease N Engl J Med 357 3 2007 228 238
8. W.J. Sandborn, S. Schreiber, and B.G. Feagan Certolizumab pegol for active Crohn's disease: a placebo-controlled, randomized trial Clin Gastroenterol Hepatol 9 8 2011 670 678.e3
9. W.J. Sandborn, J.F. Colombel, R. Enns International Efficacy of Natalizumab as Active Crohn's Therapy (ENACT-1) Trial Group; Evaluation of Natalizumab as Continuous Therapy (ENACT-2) Trial Group Natalizumab induction and maintenance therapy for Crohn's disease N Engl J Med 353 18 2005 1912 1925
10. G. Bloomgren, S. Richman, and C. Hotermans Risk of natalizumab-associated progressive multifocal leukoencephalopathy N Engl J Med 366 20 2012 1870 1880
11. W.J. Sandborn, B.G. Feagan, P. Rutgeerts GEMINI 2 Study Group Vedolizumab as induction and maintenance therapy for Crohn's disease N Engl J Med 369 8 2013 711 721
12. W.J. Sandborn, C. Gasink, L.L. Gao CERTIFI Study Group Ustekinumab induction and maintenance therapy in refractory Crohn's disease N Engl J Med 367 16 2012 1519 1528
13. A. Cipriani, J.P. Higgins, J.R. Geddes, and G. Salanti Conceptual and technical challenges in network meta-analysis Ann Intern Med 159 2 2013 130 137
14. E.J. Mills, J.P. Ioannidis, K. Thorlund, H.J. Schünemann, M.A. Puhan, and G.H. Guyatt How to use an article reporting a multiple treatment comparison meta-analysis JAMA 308 12 2012 1246 1253
15. F. Song, D.G. Altman, A.M. Glenny, and J.J. Deeks Validity of indirect comparison for estimating efficacy of competing interventions: empirical evidence from published meta-analyses BMJ 326 7387 2003 472
16. R.W. Stidham, T.C. Lee, and P.D. Higgins Systematic review with network meta-analysis: the efficacy of anti-TNF agents for the treatment of Crohn's disease Aliment Pharmacol Ther 39 12 2014 1349 1362
17. A. Liberati, D.G. Altman, and J. Tetzlaff The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate healthcare interventions: explanation and elaboration BMJ 339 2009 b2700
18. A.C. Ford, W.J. Sandborn, K.J. Khan, S.B. Hanauer, N.J. Talley, and P. Moayyedi Efficacy of biological therapies in inflammatory bowel disease: systematic review and meta-analysis Am J Gastroenterol 106 4 2011 644 659 quiz 660
19. P. Schoenfeld, D. Cook, F. Hamilton, L. Laine, D. Morgan, W. Peterson Evidence-Based Gastroenterology Steering Group An evidence-based approach to gastroenterology therapy Gastroenterology 114 6 1998 1318 1325
20. R. DerSimonian, and N. Laird Meta-analysis in clinical trials Control Clin Trials 7 3 1986 177 188
21. J.P. Higgins, S.G. Thompson, J.J. Deeks, and D.G. Altman Measuring inconsistency in meta-analyses BMJ 327 7414 2003 557 560
22. M. Egger, G. Davey Smith, M. Schneider, and C. Minder Bias in meta-analysis detected by a simple, graphical test BMJ 315 7109 1997 629 634
23. G. Lu, and A.E. Ades Combination of direct and indirect evidence in mixed treatment comparisons Stats Med 23 20 2004 3105 3124
24. J.P. Jansen, R. Fleurence, and B. Devine Interpreting indirect treatment comparisons and network meta-analysis for health-care decision making: report of the ISPOR Task Force on Indirect Treatment Comparisons Good Research Practices: part 1 Value Health 14 4 2011 417 428
25. S.B. Hanauer, W.J. Sandborn, and P. Rutgeerts Human anti-tumor necrosis factor monoclonal antibody (adalimumab) in Crohn's disease: the CLASSIC-I trial Gastroenterology 130 2 2006 323 333 quiz 591
26. M. Lémann, J.Y. Mary, B. Duclos Groupe d'Etude Therapeutique des Affections Inflammatoires du Tube Digestif (GETAID) Infliximab plus azathioprine for steroid-dependent Crohn's disease patients: a randomized placebo-controlled trial Gastroenterology 130 4 2006 1054 1061
27. S.R. Targan, S.B. Hanauer, S.J. van Deventer Crohn's Disease cA2 Study Group A short-term study of chimeric monoclonal antibody cA2 to tumor necrosis factor alpha for Crohn's disease N Engl J Med 337 15 1997 1029 1035
28. S. Ghosh, E. Goldin, F.H. Gordon Natalizumab Pan-European Study Group Natalizumab for active Crohn's disease N Engl J Med 348 1 2003 24 32
29. W.J. Sandborn, B.G. Feagan, R.N. Fedorak Ustekinumab Crohn's Disease Study Group A randomized trial of Ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with moderate-to-severe Crohn's disease Gastroenterology 135 4 2008 1130 1141
30. B.G. Feagan, G.R. Greenberg, and G. Wild Treatment of active Crohn's disease with MLN0002, a humanized antibody to the alpha4beta7 integrin [published correction appears in Clin Gastroenterol Hepatol. 2009;7(4):494] Clin Gastroenterol Hepatol 6 12 2008 1370 1377
31. P. Rutgeerts, G. D'Haens, and S. Targan Efficacy and safety of retreatment with anti-tumor necrosis factor antibody (infliximab) to maintain remission in Crohn's disease Gastroenterology 117 4 1999 761 769
32. W.J. Sandborn, S.B. Hanauer, and P. Rutgeerts Adalimumab for maintenance treatment of Crohn's disease: results of the CLASSIC II trial Gut 56 9 2007 1232 1239
33. S. Schreiber, M. Khaliq-Kareemi, I.C. Lawrance PRECISE 2 Study Investigators Maintenance therapy with certolizumab pegol for Crohn's disease [published correction appears in N Engl J Med. 2007;357(13):1357] N Engl J Med 357 3 2007 239 250
34. F.H. Gordon, C.W. Lai, and M.I. Hamilton A randomized placebo-controlled trial of a humanized monoclonal antibody to alpha4 integrin in active Crohn's disease Gastroenterology 121 2 2001 268 274
35. B.E. Sands, R. Kozarek, and J. Spainhour Safety and tolerability of concurrent natalizumab treatment for patients with Crohn's disease not in remission while receiving infliximab Inflamm Bowel Dis 13 1 2007 2 11
36. S. Schreiber, P. Rutgeerts, R.N. Fedorak CDP870 Crohn's Disease Study Group A randomized, placebo-controlled trial of certolizumab pegol (CDP870) for treatment of Crohn's disease [published correction appears in Gastroenterology. 2005;129(5):1808. Dosage error in article text] Gastroenterology 129 3 2005 807 818
37. S.R. Targan, B.G. Feagan, R.N. Fedorak International Efficacy of Natalizumab in Crohn's Disease Response and Remission (ENCORE) Trial Group Natalizumab for the treatment of active Crohn's disease: results of the ENCORE Trial Gastroenterology 132 5 2007 1672 1683
38. T.A. Winter, J. Wright, S. Ghosh, J. Jahnsen, A. Innes, and P. Round Intravenous CDP870, a PEGylated Fab' fragment of a humanized antitumour necrosis factor antibody, in patients with moderate-to-severe Crohn's disease: an exploratory study Aliment Pharmacol Ther 20 11-12 2004 1337 1346
39. J.F. Colombel, D.A. Schwartz, and W.J. Sandborn Adalimumab for the treatment of fistulas in patients with Crohn's disease Gut 58 7 2009 940 948
40. D.H. Present, P. Rutgeerts, and S. Targan Infliximab for the treatment of fistulas in patients with Crohn's disease N Engl J Med 340 18 1999 1398 1405
41. B.E. Sands, M.A. Blank, K. Patel, S.J. van Deventer ACCENT II Study Long-term treatment of rectovaginal fistulas in Crohn's disease: response to infliximab in the ACCENT II Study Clin Gastroenterol Hepatol 2 10 2004 912 920
42. P. Rutgeerts, B.G. Feagan, and G.R. Lichtenstein Comparison of scheduled and episodic treatment strategies of infliximab in Crohn's disease Gastroenterology 126 2 2004 402 413
43. G. Van Assche, S. Vermeire, and V. Ballet Switch to adalimumab in patients with Crohn's disease controlled by maintenance infliximab: prospective randomised SWITCH trial Gut 61 2 2012 229 234
44. S. Singh, S. Garg, Z. Wang, M.H. Murad, and E.V. Loftus Comparative efficacy of biologic therapy in patients with ulcerative colitis: a systematic review and indirect treatment comparison meta-analysis Gastroenterology 146 5 2014 S384
45. M.T. Osterman, K. Haynes, and E. Delzell Comparative effectiveness of infliximab and adalimumab for Crohn's disease Clin Gastroenterol Hepatol 12 5 2014 811 817.e3